3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Obesity
9
Endometrial Neoplasms
4
Prostatic Neoplasms
2
Overweight
2
Endometrial Hyperplasia
2
Diabetes Mellitus
2
Breast Neoplasms
2
Weight Loss
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Opioid-Related Disorders
1
Metabolic Syndrome
1
Lymphoma, Follicular
1
Insulin Resistance
1
Inflammation
1
Hyperplasia
1
Dyslipidemias
1
Colorectal Neoplasms
1
Interventions
Ultrasonic Waves
1
Tirzepatide
1
Therapeutics
1
Standard of Care
1
Psilocybin
1
Olanzapine
1
Midazolam
1
Lidocaine
1
Educational Status
1
Dosage Forms
1
Buprenorphine, Naloxone Drug Combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Opioid-Related Disorders
×
Tirzepatide
×
1 year
×
Clear all
NCT06651177
2026-05-22
TAB
University of Cincinnati
Phase 2
Recruiting
310 enrolled